Translational Research: Assay Development
The identification and testing of agents acting through a particular target that may modify a disease’s course typically require a set of reliable and reproducible assays to demonstrate the efficacy, selectivity, and potency of the potential therapeutic candidate. Such assays may be used to identify hits from high throughput screening campaigns, refine peptides by molecular panning, or assess in vivo properties of agents.
Starting Points
-
Disease
Biology -
Unvalidated
TargetTarget IDPutative
Targets -
Nominated
TargetAssay DevelopmentScreenable
Assays -
Target AssayScreeningHits and
Starting Points -
HitHit to LeadLead Series
-
Lead
CompoundLead
OptimizationPotential
Therapeutic
Leads -
Pre‑clinical
CandidatePre‑clinical
DevelopmentClinical
Therapeutic
Candidate -
Clinical
CandidateClinical
DevelopmentClinical Proof
of Concept -
Licensing and
Commercializa-
tion PartnersMarket-ready
Therapeutics
Outcomes and Resources
NIDDK-Specific Funding Opportunities
- PA-16-374, Assay Development and Screening to Discover Therapeutic or Imaging Agents for Diseases of Interest to the NIDDK (R01)
Related Resources
- Academic Drug Discovery Consortium
- NIH Molecular Libraries and Imaging
- PubChem
- NIDDK Small Business Programs
Staff Contacts
For questions regarding this topic, please contact Dr. Aaron Pawlyk.